Salim Yazji

976 total citations
29 papers, 738 citations indexed

About

Salim Yazji is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Salim Yazji has authored 29 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Molecular Biology and 11 papers in Immunology. Recurrent topics in Salim Yazji's work include Lymphoma Diagnosis and Treatment (5 papers), Macrophage Migration Inhibitory Factor (5 papers) and Peptidase Inhibition and Analysis (4 papers). Salim Yazji is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Macrophage Migration Inhibitory Factor (5 papers) and Peptidase Inhibition and Analysis (4 papers). Salim Yazji collaborates with scholars based in United States, Germany and United Kingdom. Salim Yazji's co-authors include Francis J. Giles, Anthony W. Tolcher, Kyle D. Holen, Glenn Liu, Alejandro D. Ricart, Geoffrey R. Weiss, Mark R. Albertini, George Wilding, Chee M. Ng and Garry Schwartz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Salim Yazji

28 papers receiving 719 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Salim Yazji United States	12	303	220	186	155	153	29	738
Pia Klausen Denmark	16	387 1.3×	246 1.1×	105 0.6×	118 0.8×	291 1.9×	33	928
John Galbincea United States	10	361 1.2×	293 1.3×	85 0.5×	106 0.7×	66 0.4×	13	636
Carlos Barranco Spain	16	174 0.6×	273 1.2×	103 0.6×	179 1.2×	96 0.6×	40	793
Simon Tickle United Kingdom	12	393 1.3×	228 1.0×	60 0.3×	61 0.4×	135 0.9×	13	925
Yasumasa Monobe Japan	13	199 0.7×	188 0.9×	88 0.5×	154 1.0×	81 0.5×	75	856
H Steininger Germany	18	208 0.7×	230 1.0×	57 0.3×	110 0.7×	256 1.7×	37	887
Jason W. Bauer United States	9	295 1.0×	293 1.3×	121 0.7×	43 0.3×	978 6.4×	10	1.6k
Consuelo Anzilotti United Kingdom	17	258 0.9×	455 2.1×	78 0.4×	64 0.4×	389 2.5×	24	1.1k
Mark Biondo Australia	14	183 0.6×	110 0.5×	33 0.2×	28 0.2×	297 1.9×	25	702
Alexandra S. Worobec United States	13	150 0.5×	202 0.9×	76 0.4×	99 0.6×	850 5.6×	16	1.0k

Countries citing papers authored by Salim Yazji

Since Specialization

Citations

This map shows the geographic impact of Salim Yazji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salim Yazji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salim Yazji more than expected).

Fields of papers citing papers by Salim Yazji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Salim Yazji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salim Yazji. The network helps show where Salim Yazji may publish in the future.

Co-authorship network of co-authors of Salim Yazji

This figure shows the co-authorship network connecting the top 25 collaborators of Salim Yazji. A scholar is included among the top collaborators of Salim Yazji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Salim Yazji. Salim Yazji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yazji, Salim, Philip Helliwell, Andra Bălănescu, et al.. (2025). Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic Arthritis. The Journal of Rheumatology. 52(4). jrheum.2024–1149. 1 indexed citations

Yu, Evan Y., Luke T. Nordquist, Salim Yazji, et al.. (2024). A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS5111–TPS5111.

Yu, Evan Y., Salim Yazji, Yisrael Katz, et al.. (2024). A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). TPS241–TPS241. 3 indexed citations

Wang, Michael, P. Connor Johnson, Salim Yazji, et al.. (2024). A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL). Blood. 144(Supplement 1). 1743–1743. 2 indexed citations

Mahalingam, Devalingam, Manish R. Patel, Jasgit C. Sachdev, et al.. (2016). Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors. Cancer Research. 76(14_Supplement). CT046–CT046. 1 indexed citations

Mahalingam, Devalingam, Manish R. Patel, Jasgit C. Sachdev, et al.. (2016). Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study. Annals of Oncology. 27. vi116–vi116. 3 indexed citations

Rosen, Lee S., Patricia LoRusso, Wen Wee, et al.. (2016). A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Investigational New Drugs. 34(5). 604–613. 62 indexed citations

Mahalingam, Devalingam, Manish R. Patel, Jasgit C. Sachdev, et al.. (2015). First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 2518–2518. 6 indexed citations

Liu, Xiaochun, Deyaa Adib, Hila Barak, Richard M. Goldberg, & Salim Yazji. (2015). Development of a phase Ib/IIa proof-of-concept study of imalumab (BAX69), a first-in-class anti-macrophage migration inhibitory factor (MIF) antibody, as the 3^rd or 4^th line treatment in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(15_suppl). TPS3633–TPS3633. 5 indexed citations

10.

Reichardt, Peter, Jean‐Yves Blay, Hans Gelderblom, et al.. (2012). Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Annals of Oncology. 23(7). 1680–1687. 97 indexed citations

11.

Rosen, Lee S., Patricia LoRusso, Wen Wee, et al.. (2011). Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. Cancer Research. 71(8_Supplement). 4716–4716. 18 indexed citations

12.

Reichardt, Peter, Jean‐Yves Blay, Hans Gelderblom, et al.. (2010). Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.. Journal of Clinical Oncology. 28(15_suppl). 10017–10017. 25 indexed citations

13.

Ricart, Alejandro D., Anthony W. Tolcher, Glenn Liu, et al.. (2008). Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study. Clinical Cancer Research. 14(23). 7924–7929. 130 indexed citations

14.

Yazji, Salim, et al.. (2007). Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). Journal of Clinical Oncology. 25(18_suppl). 5094–5094. 16 indexed citations

15.

Cranmer, Lee D., A. Y. Bedikian, Antoni Ribas, et al.. (2006). Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic melanoma. Journal of Clinical Oncology. 24(18_suppl). 8011–8011. 9 indexed citations

16.

Valle, Juan W., et al.. (2006). Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic adenocarcinoma of the pancreas (MPC). Journal of Clinical Oncology. 24(18_suppl). 4111–4111. 4 indexed citations

17.

Yazji, Salim, Francis J. Giles, Apostolia M. Tsimberidou, et al.. (2003). Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 17(11). 2101–2106. 65 indexed citations

18.

Bellm, Lisa A., Francis J. Giles, Rebecca Redman, & Salim Yazji. (2002). Iseganan HCl: a novel antimicrobial agent. Expert Opinion on Investigational Drugs. 11(8). 1161–1170. 42 indexed citations

19.

Hosing, Chitra, Mark F. Munsell, Salim Yazji, et al.. (2002). Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Annals of Oncology. 13(3). 450–459. 52 indexed citations

20.

Rodríguez, José, Mark F. Munsell, Salim Yazji, et al.. (2001). Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas. Journal of Clinical Oncology. 19(17). 3766–3770. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact